252 related articles for article (PubMed ID: 23943799)
1. Notch1 is required for Kras-induced lung adenocarcinoma and controls tumor cell survival via p53.
Licciulli S; Avila JL; Hanlon L; Troutman S; Cesaroni M; Kota S; Keith B; Simon MC; Puré E; Radtke F; Capobianco AJ; Kissil JL
Cancer Res; 2013 Oct; 73(19):5974-84. PubMed ID: 23943799
[TBL] [Abstract][Full Text] [Related]
2. Notch1 Deficiency Induces Tumor Cell Accumulation Inside the Bronchiolar Lumen and Increases TAZ Expression in an Autochthonous
Meder L; Florin A; Ozretić L; Nill M; Koker M; Meemboor S; Radtke F; Diehl L; Ullrich RT; Odenthal M; Büttner R; Heukamp LC
Pathol Oncol Res; 2021; 27():596522. PubMed ID: 34257546
[No Abstract] [Full Text] [Related]
3. Opposing role of Notch1 and Notch2 in a Kras(G12D)-driven murine non-small cell lung cancer model.
Baumgart A; Mazur PK; Anton M; Rudelius M; Schwamborn K; Feuchtinger A; Behnke K; Walch A; Braren R; Peschel C; Duyster J; Siveke JT; Dechow T
Oncogene; 2015 Jan; 34(5):578-88. PubMed ID: 24509876
[TBL] [Abstract][Full Text] [Related]
4. Activated Notch1 induces lung adenomas in mice and cooperates with Myc in the generation of lung adenocarcinoma.
Allen TD; Rodriguez EM; Jones KD; Bishop JM
Cancer Res; 2011 Sep; 71(18):6010-8. PubMed ID: 21803744
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of role of Notch3 signaling pathway in human lung cancer cells.
Hassan WA; Yoshida R; Kudoh S; Motooka Y; Ito T
J Cancer Res Clin Oncol; 2016 May; 142(5):981-93. PubMed ID: 26838758
[TBL] [Abstract][Full Text] [Related]
6. Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma.
Meylan E; Dooley AL; Feldser DM; Shen L; Turk E; Ouyang C; Jacks T
Nature; 2009 Nov; 462(7269):104-7. PubMed ID: 19847165
[TBL] [Abstract][Full Text] [Related]
7.
Deneka AY; Kopp MC; Nikonova AS; Gaponova AV; Kiseleva AA; Hensley HH; Flieder DB; Serebriiskii IG; Golemis EA
Cancer Res; 2021 Jul; 81(13):3717-3726. PubMed ID: 34006524
[TBL] [Abstract][Full Text] [Related]
8. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
[TBL] [Abstract][Full Text] [Related]
9. Modification of α2,6-sialylation mediates the invasiveness and tumorigenicity of non-small cell lung cancer cells in vitro and in vivo via Notch1/Hes1/MMPs pathway.
Yuan Q; Chen X; Han Y; Lei T; Wu Q; Yu X; Wang L; Fan Z; Wang S
Int J Cancer; 2018 Nov; 143(9):2319-2330. PubMed ID: 29981167
[TBL] [Abstract][Full Text] [Related]
10. High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and EGFR [corrected] mutation.
Nunez MI; Behrens C; Woods DM; Lin H; Suraokar M; Kadara H; Hofstetter W; Kalhor N; Lee JJ; Franklin W; Stewart DJ; Wistuba II
J Thorac Oncol; 2012 May; 7(5):833-40. PubMed ID: 22729036
[TBL] [Abstract][Full Text] [Related]
11. Impaired AKT signaling and lung tumorigenesis by PIERCE1 ablation in KRAS-mutant non-small cell lung cancer.
Roh JI; Lee J; Sung YH; Oh J; Hyeon DY; Kim Y; Lee S; Devkota S; Kim HJ; Park B; Nam T; Song Y; Kim Y; Hwang D; Lee HW
Oncogene; 2020 Sep; 39(36):5876-5887. PubMed ID: 32728173
[TBL] [Abstract][Full Text] [Related]
12. Loss of p53 attenuates the contribution of IL-6 deletion on suppressed tumor progression and extended survival in Kras-driven murine lung cancer.
Tan X; Carretero J; Chen Z; Zhang J; Wang Y; Chen J; Li X; Ye H; Tang C; Cheng X; Hou N; Yang X; Wong KK
PLoS One; 2013; 8(11):e80885. PubMed ID: 24260500
[TBL] [Abstract][Full Text] [Related]
13. PKC
Garg R; Cooke M; Benavides F; Abba MC; Cicchini M; Feldser DM; Kazanietz MG
Cancer Res; 2020 Dec; 80(23):5166-5173. PubMed ID: 32994205
[TBL] [Abstract][Full Text] [Related]
14. Mutation of TP53 and alteration of p14(arf) expression in EGFR- and KRAS-mutated lung adenocarcinomas.
Cortot AB; Younes M; Martel-Planche G; Guibert B; Isaac S; Souquet PJ; Commo F; Girard P; Fouret P; Brambilla E; Hainaut P; Soria JC
Clin Lung Cancer; 2014 Mar; 15(2):124-30. PubMed ID: 24169260
[TBL] [Abstract][Full Text] [Related]
15. CD44 promotes Kras-dependent lung adenocarcinoma.
Zhao P; Damerow MS; Stern P; Liu AH; Sweet-Cordero A; Siziopikou K; Neilson JR; Sharp PA; Cheng C
Oncogene; 2013 Oct; 32(43):5186-90. PubMed ID: 23208496
[TBL] [Abstract][Full Text] [Related]
16. The p53 Target Gene SIVA Enables Non-Small Cell Lung Cancer Development.
Van Nostrand JL; Brisac A; Mello SS; Jacobs SB; Luong R; Attardi LD
Cancer Discov; 2015 Jun; 5(6):622-35. PubMed ID: 25813352
[TBL] [Abstract][Full Text] [Related]
17. Mutationally activated PIK3CA(H1047R) cooperates with BRAF(V600E) to promote lung cancer progression.
Trejo CL; Green S; Marsh V; Collisson EA; Iezza G; Phillips WA; McMahon M
Cancer Res; 2013 Nov; 73(21):6448-61. PubMed ID: 24019382
[TBL] [Abstract][Full Text] [Related]
18. ERK3/MAPK6 is required for KRAS-mediated NSCLC tumorigenesis.
Bogucka K; Marini F; Rosigkeit S; Schloeder J; Jonuleit H; David K; Schlackow M; Rajalingam K
Cancer Gene Ther; 2021 May; 28(5):359-374. PubMed ID: 33070159
[TBL] [Abstract][Full Text] [Related]
19. Interferon regulatory factor 4 (IRF4) is overexpressed in human non‑small cell lung cancer (NSCLC) and activates the Notch signaling pathway.
Qian Y; Du Z; Xing Y; Zhou T; Chen T; Shi M
Mol Med Rep; 2017 Nov; 16(5):6034-6040. PubMed ID: 28849037
[TBL] [Abstract][Full Text] [Related]
20. Pathobiology of Notch2 in lung cancer.
Motooka Y; Fujino K; Sato Y; Kudoh S; Suzuki M; Ito T
Pathology; 2017 Aug; 49(5):486-493. PubMed ID: 28666642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
